Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
Immunity · 2025-04 · 58 (4) · 926-945.e10
DOI: 10.1016/j.immuni.2025.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2025-04. Verfasst von Mohamed-Reda Benmebarek und 24 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, National Institutes of Health, Bet…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Vascular Endothelial Growth Factor A, B-Cell Activating Factor, Interleukin-12. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, NCI NIH HHS, Office of Intramural Training and Education.
Abstract (Originalsprache)
Anti-vascular endothelial growth factor (VEGF) treatment has shown clinical activity together with immune checkpoint blockade (ICB), but the exact mechanism is not known. We show that VEGF blockade in combination with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) + anti-programmed death-ligand 1 (PD-L1) in cholangiocarcinoma (CCA) potentiated a multimodal mechanism dependent on B cell activating factor (BAFF), leading to a proinflammatory B cell response. It led to a BAFF- and interleukin (IL)-12-dependent expansion and rewiring of T regulatory cells (Tregs) toward an anti-tumor T helper-1 (Th-1)-like fragile state. We translated this approach to the clinic and observed immunological changes characterized by Treg cell expansion and rewiring toward fragile and unstable states. We explored the effect of VEGF receptor 2 (VEGFR2) signaling on Treg cell transcriptional programming and established a mouse model ablating VEGFR2 expression on Treg cells. This study reveals the immunological interplay resulting from targeting VEGF together with CTLA-4 and PD-L1 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
- Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Center for Interventional Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Förderung
- Intramural NIH HHS
- NCI NIH HHS
- Office of Intramural Training and Education
- Frederick National Laboratory for Cancer Research
- National Cancer Institute
- AstraZeneca
- Genentech
- Cholangiocarcinoma Foundation
Zitieren
APA
Benmebarek, M. R., Oguz, C., Seifert, M., Ruf, B., Myojin, Y., Bauer, K. C., Huang, P., Ma, C., Villamor-Payà, M., Rodriguez-Matos, F., Soliman, M., Trehan, R., Monge, C., Xie, C., Kleiner, D. E., Wood, B. J., Levy, E. B., Budhu, A., Kedei, N., …, & Greten, T. F. (2025). Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity, 58(4), 926-945.e10. https://doi.org/10.1016/j.immuni.2025.02.017
Vancouver
Benmebarek MR, Oguz C, Seifert M, Ruf B, Myojin Y, Bauer KC, et al. Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity. 2025;58(4):926-945.e10. doi:10.1016/j.immuni.2025.02.017
BibTeX
@article{Benmebarek2025,
author = {Benmebarek, Mohamed-Reda and Oguz, Cihan and Seifert, Matthias and Ruf, Benjamin and Myojin, Yuta and Bauer, Kylynda C and Huang, Patrick and Ma, Chi and Villamor-Payà, Marina and Rodriguez-Matos, Francisco and Soliman, Marlaine and Trehan, Rajiv and Monge, Cecilia and Xie, Changqing and Kleiner, David E and Wood, Bradford J and Levy, Elliot B and Budhu, Anuradha and Kedei, Noemi and Mayer, Christian T and Wang, Xin Wei and Lack, Justin and Telford, William and Korangy, Firouzeh and Greten, Tim F},
title = {Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME},
journal = {Immunity},
year = {2025},
volume = {58},
number = {4},
pages = {926--945.e10},
doi = {10.1016/j.immuni.2025.02.017}
}
EUVIMED